William D. McClellan Jr. - 07 Jun 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC

Role: Director
Signature: /s/ Tracy Herson, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 07 Jun 2023
Net transactions value: +$177,321
Form type: 4
Filing time: 09 Jun 2023, 16:20:37 UTC
Previous filing: 04 Apr 2023
Next filing: 01 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RETA	Class A common stock	Award	$9,923	+106	+2.5%	$93.61	4,335	07 Jun 2023	Direct	F1, F2
transaction	RETA	Class A common stock	Award	$157,452	+1,682	+39%	$93.61	6,017	07 Jun 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RETA	Stock Option (right-to-buy)	Award	$9,947	+135		$73.68	135	07 Jun 2023	Class A common stock	135	$93.61	Direct	F3, F4
transaction	RETA	Stock Option (right-to-buy)	Award	$0	+2,137		$0.000000	2,137	07 Jun 2023	Class A common stock	2,137	$93.61	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares represent Restricted Stock Units (RSUs), which vest on June 5, 2024, subject to continued service through the vesting date.
F2	These RSUs were issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $9,923.
F3	The option vests in 4 equal installments on September 7, 2023, December 7, 2023, March 7, 2024, and June 5, 2024, subject to continued service through each vesting date.
F4	This option was issued to the reporting person pursuant to the Reata Non-Employee Director Compensation Policy in lieu of future director fees of $9,947.